Safety and efficacy of brimonidine in children with glaucoma

Journal of AAPOS

Volumn 5, Issue 5, 2001, Pages 281-284

  Enyedi, Laura B ^a   Freedman, Sharon F ^a,b  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHYPERTENSIVE AGENT; BRIMONIDINE; EYE DROPS; QUINOXALINE DERIVATIVE;

ADOLESCENT; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CHEMICALLY INDUCED DISORDER; CHILD; CLINICAL TRIAL; DRUG EFFECT; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; MALE; OCULOPLETHYSMOGRAPHY; PRESCHOOL CHILD; SAFETY;

ADOLESCENT; ADRENERGIC ALPHA-AGONISTS; ANTIHYPERTENSIVE AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; CHILD; CHILD, PRESCHOOL; FEMALE; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; MALE; OPHTHALMIC SOLUTIONS; QUINOXALINES; SAFETY; TONOMETRY, OCULAR;

EID: 0035487977     PISSN: 10918531     EISSN: None     Source Type: Journal    
DOI: 10.1067/mpa.2001.117571     Document Type: Article

References (13)

1. Toris CB, Gleason ML, Camras CB, Yablonski ME. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol 1995;113:1514-7.
2. Schuman J. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol 1996; 41:S27-S37.
3. LeBlanc R, Brimonidine Study Group 2. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Ophthalmology 1998;105:1960-7.
4. Melamed S, David R. Ongoing assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Clin Ther 2000;22:103-11.
5. Schwartzenberg G, Buys Y. Efficacy of brimonidine 0.2% as adjunctive therapy for patients with glaucoma inadequately controlled with otherwise maximal medical therapy. Ophthalmology 1999;106:1616-20.
6. Nordlund J, Pasquale L, Robin A, et al. The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine. Arch Ophthalmol 1995;113:77-83.
7. Juzych M, Robin A, Novack G. Alpha-2 agonists in glaucoma therapy. In: Zimmerman T, Kooner K, Sharir M, Fechtner R, editors. Textbook of ocular pharmacology. Philadelphia: Lippincott-Raven; 1997. p. 247-54.
8. Carlsen J, Zabriskie N, Kwon Y, Barbe M, Scott W. Apparent central nervous system depression in infants after the use of topical brimonidine. AmJ Ophthalmol 1999;128:255-6.
9. Korsch E, Grote A, Seybold M, Soditt V. Systemic adverse effects of topical treatment with brimonidine in an infant with secondary glaucoma. Eur J Pediatr 1999;158:685.
10. Derick R, Robin A, Walters T. Brimonidine tartrate: a one-month dose response study. Ophthalmol 1997;104:131-6.
11. Lee D, Gornbein J, Abrams C, Group ftGTS. The effectiveness and safety of brimonidine as mono-, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: a post hoc analysis of an open-label community trial. J Ocul Pharmacol Ther 2000;16:3-18.
12. Cantor L. The evolving pharmacotherapeutic profile of brimonidine, an α2-adrenergic agonist, after four years of continuous use. Exp Opin Pharmacother 2000;1:815-34.
13. Passo M, Palmer E, Van Buskirk E. Plasma timolol in glaucoma patients. Ophthalmology 1984;91:1361.